Richard Greil

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Richard Greil

Aug 1, 2024, 03:07 | Insight

PET-adapted BrECADD versus escBEACOPP in Hodgkin Lymphoma

Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared…

Jul 21, 2024, 21:49 | Blog

Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X, about a recent paper…

Jul 20, 2024, 17:44 | Insight

Piotr Wysocki: Who should not get dose-dense adjuvant chemotherapy in breast cancer?

Piotr Wysocki recently posted on LinkedIn: "For many years, dose-dense adjuvant chemotherapy has been considered the…

Jul 20, 2024, 10:37 | Blog

Personalized Dose-Dense Adjuvant Chemotherapy for High-Risk Early breast cancer

Ivan R. Gonzalez, Medical Oncologist at Comprehensive Oncology Center, Hospital Angeles Puebla, shared a post…

Jul 19, 2024, 13:20 | Blog

Alexios Matikas: We show for the first time the superiority of dose dense versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer

Alexios Matikas, Associate Professor of Oncology at Karolinska Institute, shared on LinkedIn: "Dose dense is…

Jul 16, 2024, 07:54 | Blog

Michael Hallek: PET-guided BrECADD versus eBEACOPP in Hodgkin lymphoma

Michael Hallek, Director of Clinic I for Internal Medicine and Associated Principle Investigator at the University…

All: 6 Posts: 1 - 100